Advertisement

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Published:August 19, 2022DOI:https://doi.org/10.1016/j.clgc.2022.08.006

      Abstract

      Background

      Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inhibitor (ICI) response and survival is unclear. We hypothesized that shorter time until start of second-line (2L) ICI would be associated with worse outcomes in aUC.

      Patients and Methods

      We performed a retrospective multi-institution cohort study in patients with aUC treated with 1L platinum-based chemotherapy, who received 2L ICI. Patients receiving switch maintenance ICI were excluded. We defined time to 2L ICI therapy as the time between the start of 1L platinum-based chemotherapy to the start of 2L ICI and categorized patients a priori into 1 of 3 groups: less than 3 months versus 3-6 months versus more than 6 months. We calculated overall response rate (ORR) with 2L ICI, progression-free survival (PFS) and overall survival (OS) from the start of 2L ICI. ORR was compared among the 3 groups using multivariable logistic regression, and PFS, OS using cox regression. Multivariable models were adjusted for known prognostic factors.

      Results

      We included 215, 215, and 219 patients in the ORR, PFS, and OS analyses, respectively, after exclusions. ORR difference did not reach statistical significance between patients with less than 3 months versus 3-6 months versus more than 6 months to 2L ICI. However, PFS (HR 1.64; 95% CI 1.02-2.63) and OS (HR 1.77; 95% CI 1.10-2.84) was shorter among those with time to 2L ICI less than 3 months compared to those who initiated 2L ICI more than 6 months.

      Conclusion

      Among patients with aUC treated with 2L ICI, time to 2L ICI less than 3 months was associated with lower, but not significantly different ORR, but shorter PFS and OS compared to 2L ICI more than 6 months. This highlights potential cross resistance mechanisms between ICI and platinum-based chemotherapy.

      Keywords

      Abbreviations:

      1L (first line), 2L (second line), auc (advanced urothelial carcinoma), CI (confidence interval), FDA (Food and Drug Administration), HR (hazard ratio), DDR (DNA damage repair and response), ICI (immune checkpoint inhibitors), MIBC (muscle invasive bladder cancer), Mo (months), NAC (neoadjuvant chemotherapy), ORR (observed response rate), OS (overall survival), PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), PFS (progression-free survival), SG (sacituzumab govitecan), TME (tumor microenvironment), UC (urothelial carcinoma)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. version 3 [Internet]. [cited 2022 Jan 20] Available at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
        • von der Maase H
        • Hansen SW
        • Roberts JT
        • et al.
        Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
        J Clin Oncol. 2000; 18: 3068-3077
        • Patel MR
        • Ellerton J
        • Infante JR
        • et al.
        Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
        Lancet Oncol. 2018; 19: 51-64
        • Galsky MD
        • Saci A
        • Szabo PM
        • et al.
        Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275.
        Clin Cancer Res. 2020; 26: 5120-5128
        • Bellmunt J
        • de Wit R
        • Vaughn DJ
        • et al.
        Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
        N Engl J Med. 2017; 376: 1015-1026
        • Balar AV
        • Galsky MD
        • Rosenberg JE
        • et al.
        Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicenter, phase II trial.
        The Lancet. 2017; 389: 67-76
        • Martin LP
        • Hamilton TC
        • Schilder RJ.
        Platinum resistance: the role of DNA repair pathways.
        Clin Cancer Res. 2008; 14: 1291-1295
        • Bokemeyer C
        • Kollmannsberger C
        • Harstrick A
        • et al.
        Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
        Int J Cancer. 1999; 83: 848-851
        • Sonpavde G
        • Pond GR
        • Fougeray R
        • et al.
        Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase II Trials.
        Eur Urol. 2013; 63: 717-723
        • Matsuo K
        • Lin YG
        • Roman LD
        • Sood AK.
        Overcoming Platinum Resistance in Ovarian Carcinoma.
        Expert Opin Investig Drugs. 2010; 19: 1339-1354
        • Le Saux O
        • Ray-Coquard I
        • Labidi-Galy SI
        Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.
        Semin Cancer Biol. 2021; 77: 127-143
        • Sweis RF
        • Spranger S
        • Bao R
        • et al.
        Molecular Drivers of the Non-T Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
        Cancer Immunol Res. 2016; 4: 563-568
        • Khaki AR
        • Li A
        • Diamantopoulos LN
        • et al.
        Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.
        Cancer. 2020; 126: 1208-1216
        • Khaki AR
        • Li A
        • Diamantopoulos LN
        • et al.
        A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
        Eur Urol Oncol. 2021; 4: 464-472
        • Harris PA
        • Taylor R
        • Thielke R
        • Payne J
        • Gonzalez N
        • Conde JG.
        Research Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Harris PA
        • Taylor R
        • Minor BL
        • et al.
        The REDCap Consortium: Building an International Community of Software Platform Partners.
        J Biomed Inform. 2019; 95103208
        • Bellmunt J
        • Choueiri TK
        • Fougeray R
        • et al.
        Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
        J Clin Oncol. 2010; 28: 1850-1855
        • Stewart TF
        • Kotha NV
        • Dzimitrowicz HE
        • et al.
        Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
        J Clin Oncol. 2021; 39 (15_supple16515): e16515
        • Sonpavde G
        • Manitz J
        • Gao C
        • et al.
        Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
        J Urol. 2020; 204: 1173-1179
        • Grivas P
        • Loriot Y
        • Morales-Barrera R
        • et al.
        Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase II, open-label trial (ATLAS).
        BMC Cancer. 2021; 21: 593
        • Grivas P
        • Mortazavi A
        • Picus J
        • et al.
        Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
        Cancer. 2019; 125: 533-540
        • Powles T
        • Carroll D
        • Chowdhury S
        • et al.
        An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
        Nat Med. 2021; 27: 793-801
        • Grivas P
        • Pouessel D
        • Park CH
        • et al.
        TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
        J Clin Oncol. 2022; 40 (6_suppl434): 434
        • Sadeghi S
        • Quinn DI
        • Dorff T
        • et al.
        651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC).
        Ann Oncol. 2021; 32: S678
        • Msaouel P
        • Siefker-Radtke AO
        • Sweis R
        • et al.
        705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC).
        Ann Oncol. 2020; 31: S556
        • Drakaki A
        • Rezazadeh Kalebasty A
        • Lee JL
        • et al.
        Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.
        J Clin Oncol. 2020; 38 (6_suppl): TPS591
        • Teo MY
        • Bambury RM
        • Zabor EC
        • et al.
        DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
        Clin Cancer Res. 2017; 23: 3610-3618
        • Teo MY
        • Seier K
        • Ostrovnaya I
        • et al.
        Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
        J Clin Oncol. 2018; 36: 1685-1694
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
        N Engl J Med. 2020; 383: 1218-1230